Indaptus Therapeutics, Inc. Marketable Securities, Unrealized Gain (Loss)
Indaptus Therapeutics, Inc. (INDP) reported Marketable Securities, Unrealized Gain (Loss) of $96.43 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-17.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2023-03-17
- Indaptus Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2022-12-31 was $81.30K.
- Indaptus Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2022-09-30 was $42.07K.
- Indaptus Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2022-06-30 was $17.72K.
- Indaptus Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2022-03-31 was $9.22K.
- Indaptus Therapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2022 was $96.43K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2022-12-31 | $81.30K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $123.37K derived: sum of 2 quarters · filed 2023-03-17 | $141.09K derived: sum of 3 quarters · filed 2023-03-17 | $96.43K 10-K · filed 2023-03-17 |
| 2022-09-30 | $42.07K 10-Q · filed 2022-11-10 | $59.78K derived: sum of 2 quarters · filed 2022-11-10 | $15.13K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $17.72K 10-Q · filed 2022-08-08 | $26.94K 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | $9.22K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |